[{"orgOrder":0,"company":"Cevec","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cevec Announces New License Agreement for Its Aav Manufacturing Technology Elevecta\u00ae IN Gene Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cevec"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$285.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"GERMANY","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Evotec"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Under the expansion, Bristol Myers Squibb increases its access to a novel targeted protein degradation approach. The focus will be on selected targets that are relevant to a range of neurodegenerative conditions.
Under the terms of the agreement, CEVEC grants Biogen a non-exclusive license for CEVEC’s ELEVECTA® Technology. The deal will afford Biogen the rights to use the technology across their portfolio of gene therapy products.